

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Condensed Balance Sheets(Reviewed, Not Audited)**  
**Nine Months Ended September 30, 2019 and 2018**

Unit : NT\$ Thousands

Assets		September 30, 2019		December 31, 2018		September 30, 2018	
		A m o u n t	%	A m o u n t	%	A m o u n t	%
<b>Current Assets</b>							
1100	Cash and Cash Equivalents	\$ 762,209	7	\$ 594,627	5	\$ 735,275	7
1136	Amortised cost of a financial asset – Current	-	-	-	-	3,000	-
1150	Current Investments in Debt Instrument Without Active Market	346,127	3	413,317	4	420,407	4
1160	Notes Receivable	124,611	1	131,447	1	157,140	1
1170	Notes Receivable – Related Parties	1,659,120	15	1,523,865	14	1,599,776	15
1180	Accounts Receivable	46,739	-	56,725	1	42,172	-
1200	Other Receivables	40,753	-	32,463	-	29,609	-
1210	Other Receivables –Related Parties	205,778	2	183,939	2	191,828	2
1220	Current Income Tax Assets	-	-	1,141	-	-	-
130X	Inventories	2,177,991	19	2,135,081	20	2,013,022	19
1476	Other Financial Assets- Current	6,956	-	28,632	-	36,984	-
1479	Other Assets- Current	80,530	1	74,538	1	116,425	1
11XX	<b>Total Current Assets</b>	<u>5,450,814</u>	<u>48</u>	<u>5,175,775</u>	<u>48</u>	<u>5,345,638</u>	<u>49</u>
<b>Non-Current assets</b>							
1517	Financial assets measured at fair value through other comprehensive income – Noncurrent	336,165	3	275,623	3	263,204	2
1550	Long-term Investments at Equity	909,471	8	912,366	8	849,789	8
1600	Property, Plant and Equipment	4,172,488	36	3,948,268	37	3,961,021	37
1755	Assets Appropriative Right	82,965	1	-	-	-	-
1780	Intangible Assets	25,014	-	31,899	-	30,034	-
1840	Deferred Tax Assets	196,315	2	190,871	2	184,384	2
1900	Other Non-current Assets	241,183	2	231,500	2	202,820	2
15XX	<b>Total Non-Current Assets</b>	<u>5,963,601</u>	<u>52</u>	<u>5,590,527</u>	<u>52</u>	<u>5,491,252</u>	<u>51</u>
1XXX	<b>Total Assets</b>	<u>\$ 11,414,415</u>	<u>100</u>	<u>\$ 10,766,302</u>	<u>100</u>	<u>\$ 10,836,890</u>	<u>100</u>

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Condensed Balance Sheets(Reviewed, Not Audited)**  
**Nine Months Ended September 30, 2019 and 2018**

Unit : NT\$ Thousands

Liabilities and Shareholders' Equity		September 30, 2019		December 31, 2018		September 30, 2018	
		A m o u n t	%	A m o u n t	%	A m o u n t	%
<b>Current Liabilities</b>							
2100	Short-term Borrowings	\$ 1,622,644	14	\$ 1,021,001	10	\$ 1,306,713	12
2110	Short-Term Notes and Bills Payable	68,977	1	109,977	1	92,300	1
2130	Contractual Liability – Current	24,478	-	54,390	1	34,291	-
2150	Notes Payable	34,781	-	143,158	1	184,919	2
2170	Accounts Payable	863,538	8	882,390	8	960,254	9
2200	Other Payables	521,199	5	515,268	5	505,594	5
2230	Current Income Tax Liabilities	66,121	1	74,511	1	52,521	1
2280	Lease Liabilities – Current	9,003	-	-	-	-	-
2320	Refund Liability – Current	19,400	-	-	-	-	-
2365	Other Current Liabilities	63,879	-	47,585	-	140,096	1
2399	Current Income Tax Liabilities	21,493	-	19,630	-	15,685	-
21XX	<b>Total Non-Current Liabilities</b>	<u>3,315,513</u>	<u>29</u>	<u>2,867,910</u>	<u>27</u>	<u>3,292,373</u>	<u>31</u>
<b>Non-Current Liabilities</b>							
2540	Long-term Borrowings	1,879,600	16	1,828,000	17	1,538,000	14
2570	Deferred Income Tax Liabilities	126,772	1	127,993	1	125,448	1
2580	Lease Liabilities – Uncurrent	55,981	1	-	-	-	-
2600	Other Non-Current Liabilities	189,236	2	241,242	2	211,468	2
25XX	<b>Total Non-Current Liabilities</b>	<u>2,251,589</u>	<u>20</u>	<u>2,197,235</u>	<u>20</u>	<u>1,874,916</u>	<u>17</u>
2XXX	<b>Total Liabilities</b>	<u>5,567,102</u>	<u>49</u>	<u>5,065,145</u>	<u>47</u>	<u>5,167,289</u>	<u>48</u>
<b>Equity Attributable to Owners of Parent</b>							
<b>Share Capital</b>							
3110	Ordinary Share	2,980,811	26	2,980,811	28	2,980,811	28
<b>Capital Surplus</b>							
3200	Capital Surplus	646,032	6	644,859	6	644,859	6
<b>Retained Earnings</b>							
3310	Legal Reserve	496,980	4	459,993	4	459,993	4
3320	Special Reserve	188,958	2	188,958	2	188,958	2
3350	Unappropriated Retained Earnings	1,512,897	13	1,451,784	14	1,427,625	13
<b>Other Equity Interest</b>							
3400	Other Interest	18,650	-	( 27,793)	( 1)	( 43,360)	( 1)
3500	Treasury Stock	( 28,054)	-	( 28,054)	-	( 28,054)	-
31XX	<b>Noncontrolling Interests</b>	<u>5,816,274</u>	<u>51</u>	<u>5,670,558</u>	<u>53</u>	<u>5,630,832</u>	<u>52</u>
36XX	<b>Total Shareholders' Equity</b>	<u>31,039</u>	<u>-</u>	<u>30,599</u>	<u>-</u>	<u>38,769</u>	<u>-</u>
3XXX	Significant Contingent Liability&Unrealized						
	Contractual Arrangement	5,847,313	51	5,701,157	53	5,669,601	52
<b>Noncontrolling Interests</b>							
3X2X	<b>Noncontrolling Interests</b>	<u>\$ 11,414,415</u>	<u>100</u>	<u>\$ 10,766,302</u>	<u>100</u>	<u>\$ 10,836,890</u>	<u>100</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Comprehensive Income(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2019and 2018**

Unit : NT\$ Thousands  
(EPS: NT Dollars)

Item	For the Three Months Ended September 30				For the Nine Months Ended September 30			
	2019	2019	2018	2018	2019	2019	2018	2018
	Amount	%	Amount	%	Amount	%	Amount	%
4000 Operating Revenue	\$ 1,964,045	100	\$ 2,003,713	100	\$ 5,926,510	100	\$ 5,877,127	100
5000 Operating Costs	( 1,227,489)	( 62)	( 1,285,965)	( 64)	( 3,670,557)	( 62)	( 3,685,260)	( 63)
5950 <b>Gross Profit from Operations</b>	<u>736,556</u>	<u>38</u>	<u>717,748</u>	<u>36</u>	<u>2,255,953</u>	<u>38</u>	<u>2,191,867</u>	<u>37</u>
<b>Operating Expenses</b>								
6100 Selling Expenses	( 477,950)	( 24)	( 478,977)	( 24)	( 1,470,159)	( 25)	( 1,425,914)	( 24)
6200 Administrative Expenses	( 50,614)	( 3)	( 47,523)	( 3)	( 149,128)	( 3)	( 147,700)	( 2)
6300 Research and Development Expenses	( 95,404)	( 5)	( 107,234)	( 5)	( 312,550)	( 5)	( 289,617)	( 5)
6450 Expected Credit Losses	<u>4,297</u>	<u>-</u>	<u>( 19,645)</u>	<u>( 1)</u>	<u>( 4,580)</u>	<u>-</u>	<u>( 32,628)</u>	<u>( 1)</u>
6000 <b>Total Operating Expenses</b>	<u>( 619,671)</u>	<u>( 32)</u>	<u>( 653,379)</u>	<u>( 33)</u>	<u>( 1,936,417)</u>	<u>( 33)</u>	<u>( 1,895,859)</u>	<u>( 32)</u>
6900 <b>Net Operating Income</b>	<u>116,885</u>	<u>6</u>	<u>64,369</u>	<u>3</u>	<u>319,536</u>	<u>5</u>	<u>296,008</u>	<u>5</u>
<b>Non- Operating Income and Expenses</b>								
7010 Other Revenue	9,129	1	9,076	-	31,758	1	33,983	1
7020 Other Gains and Losses	1,508	-	2,030	-	1,768	-	( 3,762)	-
7050 Finance Cost	( 11,214)	( 1)	( 9,614)	-	( 32,188)	( 1)	( 27,902)	-
7060 Share of Profit or Loss of Associates & Joint Ventures Accounted for Using Equity Method)	<u>14,518</u>	<u>1</u>	<u>57,570</u>	<u>3</u>	<u>45,056</u>	<u>1</u>	<u>78,726</u>	<u>1</u>
7000 <b>Total Non-Operating Income and Expenses</b>	<u>13,941</u>	<u>1</u>	<u>59,062</u>	<u>3</u>	<u>46,394</u>	<u>1</u>	<u>81,045</u>	<u>2</u>
7900 <b>Income Before Income Tax</b>	130,826	7	123,431	6	365,930	6	377,053	7
7950 Income Tax Expense	( 32,554)	( 2)	( 18,446)	( 1)	( 51,417)	( 1)	( 55,947)	( 1)
8200 <b>Net Income</b>	<u>\$ 98,272</u>	<u>5</u>	<u>\$ 104,985</u>	<u>5</u>	<u>\$ 314,513</u>	<u>5</u>	<u>\$ 321,106</u>	<u>6</u>

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Comprehensive Income(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2019and 2018**

Unit : NT\$ Thousands  
(EPS: NT Dollars)

Item	For the Three Months Ended September 30				For the Nine Months Ended September 30			
	2019		2018		2019		2018	
	<u>A m o u n t</u>	<u>%</u>	<u>A m o u n t</u>	<u>%</u>	<u>A m o u n t</u>	<u>%</u>	<u>A m o u n t</u>	<u>%</u>
<b>Other Comprehensive Income that will be Reclassified to Profit or Loss</b>								
8316 Unrealised Gains (Losses) on Financial assets measured at fair value through other comprehensive income	(\$ 2,382)	-	(\$ 48,078)	( 2)	\$ 92,997	1	(\$ 48,062)	( 1)
8320 Share of Other Comprehensive Income of Associates and Joint Ventures Accounted for Using Equity Method	-	-	5,146	-	-	-	6,382	-
8349 Income Tax not Related to Components of Other Comprehensive Income	-	-	-	-	-	-	2,200	-
8310 <b>Total Components of Other Comprehensive Income That Will be not Reclassified to Profit or Loss Components of Other Comprehensive Income That Will be Reclassified to Profit or Loss</b>	<u>( 2,382)</u>	<u>-</u>	<u>( 42,932)</u>	<u>( 2)</u>	<u>92,997</u>	<u>1</u>	<u>( 39,480)</u>	<u>( 1)</u>
Income Tax not Related to Components of Other Comprehensive Income								
8361 Exchange Differences on Translation of Foreign Financial Statements	( 42,667)	( 2)	( 72,078)	( 4)	( 30,407)	-	( 20,425)	-
8370 Share of Other Comprehensive Income (Loss) of Subsidiaries and Associates Accounted for Using Equity Method - Will be Reclassified to Profit	( 158)	-	-	-	76	-	79	-
8399 Income Tax Relating to Components of Other Comprehensive Income	8,534	-	14,399	1	6,082	-	4,752	-
8360 <b>Total Components of Other Comprehensive Income That Will be Reclassified to Profit or Loss</b>	<u>( 34,291)</u>	<u>( 2)</u>	<u>( 57,679)</u>	<u>( 3)</u>	<u>( 24,249)</u>	<u>-</u>	<u>( 15,594)</u>	<u>-</u>
8300 <b>Total Net Comprehensive Profit(Loss) After Tax</b>	<u>(\$ 36,673)</u>	<u>( 2)</u>	<u>(\$ 100,611)</u>	<u>( 5)</u>	<u>\$ 68,748</u>	<u>1</u>	<u>(\$ 55,074)</u>	<u>( 1)</u>
8500 <b>Total Comprehensive Income</b>	<u>\$ 61,599</u>	<u>3</u>	<u>\$ 4,374</u>	<u>-</u>	<u>\$ 383,261</u>	<u>6</u>	<u>\$ 266,032</u>	<u>5</u>
<b>Net Income (Losses) Attributable to:</b>								
8610 Shareholders of the Parent	<u>\$ 98,046</u>	<u>5</u>	<u>\$ 105,400</u>	<u>5</u>	<u>\$ 314,260</u>	<u>5</u>	<u>\$ 323,953</u>	<u>6</u>
8620 Noncontrolling Interests	<u>\$ 226</u>	<u>-</u>	<u>(\$ 415)</u>	<u>-</u>	<u>\$ 253</u>	<u>-</u>	<u>(\$ 2,847)</u>	<u>-</u>
<b>Comprehensive Income Attributable to:</b>								
8710 Shareholders of the Parent	<u>\$ 61,373</u>	<u>3</u>	<u>\$ 4,789</u>	<u>-</u>	<u>\$ 383,008</u>	<u>6</u>	<u>\$ 268,879</u>	<u>5</u>
8720 Noncontrolling Interests	<u>\$ 226</u>	<u>-</u>	<u>(\$ 415)</u>	<u>-</u>	<u>\$ 253</u>	<u>-</u>	<u>(\$ 2,847)</u>	<u>-</u>
<b>Earnings per Share</b>								
9750 <b>Diluted Earnings Per Share</b>	<u>\$</u>	<u>0.33</u>	<u>\$</u>	<u>0.36</u>	<u>\$</u>	<u>1.06</u>	<u>\$</u>	<u>1.09</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statement of Changes in Equity(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2019 and 2018**

Unit : NT\$ Thousands

	Total Equity Attributable to Owners of Parent											Non-controlling Interests	Total Equity	
	Ordinary Share	Addition al Paid-In Capital	Treasur y Stock Transac tions	change in ownership of a subsidiary	Legal Reserve	Special Reserve	Unappropri ated Retained Earnings	Exchange Differences on Translation	Other Equity	Unrealized Gains (Losses) on Financial assets measured at fair value through other comprehensive income	Unrealize d Gains(Los ses) on Available for-sale Financial A s s e t s			Treasury Stock
<b>January 1st to September 30, 2018</b>														
Equity at Beginning Of Period	\$ 2,980,811	\$ 578,416	\$ 64,935	\$ 1,308	\$ 428,920	\$ 188,958	\$ 1,319,885	(\$ 57,143 )	\$ -	\$ 85,107	(\$ 28,054 )	\$ 5,563,143	\$ 40,552	\$ 5,603,695
Corrected Retrospective Effect of number of effects	-	-	-	-	-	-	( 23,173 )	-	85,739	( 85,107 )	-	( 22,541 )	-	( 22,541 )
Balance of number Effects	2,980,811	578,416	64,935	1,308	428,920	188,958	1,296,712	( 57,143 )	85,739	-	( 28,054 )	5,540,602	40,552	5,581,154
Consolidated Profit for The Year Ended September 30, 2018	-	-	-	-	-	-	323,953	-	-	-	-	323,953	( 2,847 )	321,106
Other Comprehensive Income	-	-	-	-	-	-	2,144	( 15,594 )	( 41,624 )	-	-	( 55,074 )	-	( 55,074 )
Total Consolidated Profit for The Year Ended September 30, 2018	-	-	-	-	-	-	326,097	( 15,594 )	( 41,624 )	-	-	268,879	( 2,847 )	266,032
Appropriation and Distribution of Retained Earnings of 2017														
Legal Reserve	-	-	-	-	31,073	-	( 31,073 )	-	-	-	-	-	-	-
Cash Dividends	-	-	-	-	-	-	( 178,849 )	-	-	-	-	( 178,849 )	-	( 178,849 )
Subsidiaries Acquired Cash Dividend Payment of Parent Company	-	-	356	-	-	-	-	-	-	-	-	356	-	356
Changes in Interests for Subsidiaries	-	-	-	( 156 )	-	-	-	-	-	-	-	( 156 )	-	( 156 )
Changes in Non-controlling Interests	-	-	-	-	-	-	-	-	-	-	-	-	1,064	1,064
Disposal of Financial assets measured at fair value through other comprehensive income	-	-	-	-	-	-	14,738	-	( 14,738 )	-	-	-	-	-
<b>Balance, September 30, 2018</b>	<b>\$ 2,980,811</b>	<b>\$ 578,416</b>	<b>\$ 65,291</b>	<b>\$ 1,152</b>	<b>\$ 459,993</b>	<b>\$ 188,958</b>	<b>\$ 1,427,625</b>	<b>(\$ 72,737 )</b>	<b>\$ 29,377</b>	<b>\$ -</b>	<b>(\$ 28,054 )</b>	<b>\$ 5,630,832</b>	<b>\$ 38,769</b>	<b>\$ 5,669,601</b>
<b>January 1st to September 30, 2019</b>														
Equity at Beginning Of Period	\$ 2,980,811	\$ 578,416	\$ 65,291	\$ 1,152	\$ 459,993	\$ 188,958	\$ 1,451,784	(\$ 65,308 )	\$ 37,515	\$ -	(\$ 28,054 )	\$ 5,670,558	\$ 30,599	\$ 5,701,157
Consolidated Profit for The Year Ended September 30, 2019	-	-	-	-	-	-	314,260	-	-	-	-	314,260	253	314,513
Other Comprehensive Income	-	-	-	-	-	-	-	( 24,249 )	92,997	-	-	68,748	-	68,748
Total Consolidated Profit for The Year Ended September 30, 2019	-	-	-	-	-	-	314,260	( 24,249 )	92,997	-	-	383,008	253	383,261
Appropriation and Distribution of Retained Earnings of 2018														
Legal Reserve	-	-	-	-	36,987	-	( 36,987 )	-	-	-	-	-	-	-
Cash Dividends	-	-	-	-	-	-	( 238,465 )	-	-	-	-	( 238,465 )	-	( 238,465 )
Subsidiaries Acquired Cash Dividend Payment of Parent Company	-	-	474	-	-	-	-	-	-	-	-	474	-	474
Changes in Interests for Subsidiaries	-	-	-	699	-	-	-	-	-	-	-	699	-	699
Disposal of Financial assets measured at fair value through other comprehensive income	-	-	-	-	-	-	22,305	-	( 22,305 )	-	-	-	-	-
Changes in Non-controlling Interests	-	-	-	-	-	-	-	-	-	-	-	-	187	187
<b>Balance, September 30, 2019</b>	<b>\$ 2,980,811</b>	<b>\$ 578,416</b>	<b>\$ 65,765</b>	<b>\$ 1,851</b>	<b>\$ 496,980</b>	<b>\$ 188,958</b>	<b>\$ 1,512,897</b>	<b>(\$ 89,557 )</b>	<b>\$ 108,207</b>	<b>\$ -</b>	<b>(\$ 28,054 )</b>	<b>\$ 5,816,274</b>	<b>\$ 31,039</b>	<b>\$ 5,847,313</b>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2019 and 2018**

Unit : NT\$ Thousands

	<b>For the Nine Months Ended September 30</b>							
	<u>2</u>	<u>0</u>	<u>1</u>	<u>9</u>	<u>2</u>	<u>0</u>	<u>1</u>	<u>8</u>
<b><u>Cash Flows From (Used in) Operating Activities</u></b>								
Consolidated Profit (Loss) Before Tax	\$		365,930		\$		377,053	
Depreciation expense			185,667				185,886	
Amortized Expense			8,018				6,234	
Expected Credit Losses			4,580				32,628	
Interest Expense			32,188				27,902	
Interest Revenue		(	10,837	)	(		14,640	)
Dividend Revenue		(	9,900	)	(		10,400	)
Gain on Disposal of Property, Plant and Equipment		(	3	)	(		204	)
Share of gain (loss) of Associates and Joint Ventures								
Accounted for Using Equity Method		(	45,056	)	(		78,726	)
Notes Receivable (Include Related Parties)			75,224		(		10,843	
Accounts Receivable (Include Related Parties)		(	206,869	)	(		283,368	
Other Receivable (Include Related Parties)			4,871				3,389	
Inventories		(	49,252	)	(		321,202	)
Other Current Assets		(	9,100	)	(		33,254	)
Contractual Liability – Current		(	34,519	)	(		49,318	)
Notes Payable		(	104,697	)			60,707	
Accounts Payable		(	10,262	)			260,196	
Other Payable		(	11,784	)			86,487	
Refund Liability – Current			16,294				33,101	
Short-term Provisions			7,897		(		1,135	)
Other Current Liabilities		(	48,313	)	(		27,290	)
<b>Cash Inflow (Outflow) Generated from Operations</b>			<u>160,077</u>				<u>243,203</u>	
Interest Received			10,837				14,914	
Interest Paid		(	31,750	)	(		26,117	)
Income Taxes Paid		(	71,051	)	(		65,131	)
Income Taxes Refund			12,099				-	
Cash Dividends Received			63,032				62,166	
<b>Net Cash Flows from (used in) Operating Activities</b>			<u>143,244</u>				<u>229,035</u>	

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2019 and 2018**

Unit : NT\$ Thousands

	<b>For the Nine Months Ended September 30</b>							
	<u>2</u>	<u>0</u>	<u>1</u>	<u>9</u>	<u>2</u>	<u>0</u>	<u>1</u>	<u>8</u>
<b><u>Cash Flows From (Used in) Investing Activities</u></b>								
Decrease(Increase) in Financing Receivable	\$		23,500		\$		-	
Decrease(Increase) in Pledged Deposit			21,676		(		9,068	)
Acquired of inancial assets measured at fair value through other comprehensive income		(	17,432	)	(		24,554	)
Disposal of Financial assets measured at fair value through other comprehensive income			49,887				27,466	
Acquire of Long-term Investments at Equity		(	5,100	)			-	
Purchase of Property, Plant and Equipment		(	403,949	)	(		127,974	)
Disposal of Property, Plant and Equipment			7				262	
Purchase of Intangible Assets		(	1,186	)	(		3,899	)
Decrease(Increase) in Refundable Deposits		(	10,618				5,933	
Decrease(Increase) in Prepaid Investments			-	(			1,332	)
Decrease(Increase) in Other Non-current Assets		(	5,196	)	(		13,562	)
Changes in Interests for Subsidiaries			-	)	(		3,310	)
<b>Net Cash Flows From (Used in) Investing Activities</b>			<u>348,411</u>		(		<u>150,038</u>	
<b><u>Cash flows from (used in) Financing Activities</u></b>								
Decrease(Increase) In Short-term Borrowings			601,643				226,285	
Decrease(Increase) in Short-term Notes and Bills Payable		(	41,000	)	(		371	)
Lease Liability Principal Repayment		(	7,741	)			-	
Proceeds from Long-term Borrowings			544,000				557,000	
Repayment of Long-term Borrowings		(	473,000	)	(		698,000	)
Decrease(Increase) in Guarantee Deposits Received		(	3,002	)	(		1,579	)
Dispense Cash Dividends		(	238,465	)	(		178,849	)
Changes in Non-controlling Interests			187				930	
<b>Net cash FlowsFrom (Used in) Financing Activities</b>			<u>382,622</u>		(		<u>94,584</u>	
Effect of Exchange Rate Changes on Cash and Cash Equivalents		(	9,873	)	(		12,822	)
Net Increase (Decrease) In Cash and Cash Equivalents			167,582		(		28,409	
Cash and Cash Equivalents at Beginning of Period			<u>594,627</u>				<u>763,684</u>	
Cash and Cash Equivalents at End of Period	\$		<u>762,209</u>		\$		<u>735,275</u>	